Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00RSK
|
||||
| Former ID |
DCL000830
|
||||
| Drug Name |
GW-406381
|
||||
| Synonyms |
GW 406381; GW406381; 8-(4-ethoxyphenyl)-7-(4-methylsulfonylphenyl)-1,2,9-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Osteoarthritis; Neuropathic pain [ICD9: 338, 356.0, 356.8, 715,780; ICD10:G64, G90.0, M15-M19, M47, R52, G89] | Discontinued in Phase 3 | [536374] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H19N3O3S
|
||||
| Canonical SMILES |
CCOC1=CC=C(C=C1)C2=NN3C(=C2C4=CC=C(C=C4)S(=O)(=O)C)C=CC<br />=N3
|
||||
| InChI |
1S/C21H19N3O3S/c1-3-27-17-10-6-16(7-11-17)21-20(19-5-4-14-22-24(19)23-21)15-8-12-18(13-9-15)28(2,25)26/h4-14H,3H2,1-2H3
|
||||
| InChIKey |
NXMZBNYLCVTRGB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 478702-57-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [536374] | |
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| NF-kappa B signaling pathway | |||||
| VEGF signaling pathway | |||||
| TNF signaling pathway | |||||
| Retrograde endocannabinoid signaling | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Oxytocin signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Leishmaniasis | |||||
| Pathways in cancer | |||||
| Chemical carcinogenesis | |||||
| MicroRNAs in cancer | |||||
| Small cell lung cancer | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.